Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, ≥ 18 and \< 80 years of age.~* CD20-positive diffuse large B-cell lymphoma.~* Low-intermediate, high-intermediate, or high risk disease and/or bulky tumor (largest diameter ≥ 7.5 cm).~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~Exclusion Criteria:~* Prior treatment for diffuse large B-cell lymphoma.~* Types of non-Hodgkin's lymphoma other than diffuse large B-cell lymphoma (DLBCL).~* Central nervous system (CNS) involvement of lymphoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + rituximab + CHOP (Type: EXPERIMENTAL): Patients received bevacizumab 5 mg/kg/week on Day 1 of each cycle + rituximab 375 mg/m\^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone).
- Placebo + rituximab + CHOP (Type: ACTIVE_COMPARATOR): Patients received placebo to bevacizumab on Day 1 of each cycle + rituximab 375 mg/m\^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone).

Based on this trial design, predict the completion outcome and termination type (if applicable).